In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Spero Therapeutics (SPRO – Research Report), with a price target of $20.00. The company’s shares closed last Tuesday at $12.45. According to TipRanks.com, DeGeeter is a